Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events

Background Management of immune-related adverse events (irAEs) is important as they cause treatment interruption or discontinuation, more often seen with combination immune checkpoint inhibitor (ICI) therapy. Here, we retrospectively evaluated the safety and effectiveness of anti-interleukin-6 recep...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Namrata Singh, Maria E Suarez-Almazor, Iman Osman, Jeffrey Weber, Adi Diab, Petros Grivas, Noha Abdel-Wahab, Ala Abudayyeh, Huifang Lu, Osama Rahma, Daniel H Johnson, Chrystia M Zobniw, Van A Trinh, Juhee Song, Jeffrey A Sparks, Sabina Sandigursky, Maya Dimitrova, May Daher, Maryam Buni, Kaysia Ludford, Faisal Fa'ak, Sarah H Chung, Uma Thanarajasingam, Adewunmi Falohun, Muhammad Osama Awiwi, Nourel Hoda Tahon, Khaled M Elsayes, Emma J Montazari, Julia Chernis, Osama Abu-Shawer, Ashley M Zeman, Rafee Talukder, Jean H Tayar
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMJ Publishing Group 2023-06-01
coleção:	Journal for ImmunoTherapy of Cancer
Acesso em linha:	https://jitc.bmj.com/content/11/6/e006814.full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!